Piling On: AstraZeneca Files Sixth Manufacturer Lawsuit Against Medicare Negotiation Program
Executive Summary
Firm leans into allegations that the US government violated the Administrative Procedures Act in implementing the program. More legal actions are expected from industry once CMS announces the first list of drugs subject to negotiation. Our lawsuit tracker will keep you apprised.
You may also be interested in...
Court Could Pause Medicare Drug Price Negotiation Process Following First Hearing In IRA Litigation
Ahead of Friday’s hearing on US Chamber of Commerce's suit against HHS, attorneys discuss potential remedies and carveouts to Inflation Reduction Act's drug price negotiation provisions, harms to industry that may support a preliminary injunction, and what would prompt Supreme Court review.
Litigation Against Medicare Price Negotiation Gains Four Potential New Plaintiffs
Abbvie, Amgen, Novartis and Novo Nordisk have drugs on the list but haven’t sued yet. While they could add to the ranks of legal opposition, the Court Battle for the IRA is more about philosophy than numbers.
Price Negotiation And Sickle Cell ‘Cures’: Dueling Biopharma Headlines This Fall
The two sides of the US public’s perceptions of the biopharma industry are likely to dominate the headlines this fall. Will the industry emerge defined by innovation and hope for better health? Or by massive profits protected by litigation?